CD274 and non-small cell lung carcinoma: In the 5-year follow-up analysis of KEYNOTE-024, the median OS was 26.3 months (95% CI, 18.3–40.4 months) for pembrolizumab and 13.4 months (9.4–18.3) for platinum-based chemotherapy for NSCLC with PD-L1 expression ≥50% [6].